DCAF13 and cancer: Notably, the pharmacogenomic CellMiner Cross-Database (https://discover.nci.nih.gov) shows significant correlations between the expression of DCAF13 and cytotoxicity of the clinical TOP1 inhibitors topotecan and irinotecan across cancer cell lines (Supplementary Data Fig. 6c).